65 results about "Liver tissue" patented technology

The application discloses a lactobacillus crispatus based on multiple targets to realize anti-aging effect and application of transformation of glycyrrhiza for efficiency enhancement, and belongs to the technical field of microorganisms and the technical field of medicine. The lactobacillus crispatus CCFM1362 provided in the application can ferment glycyrrhiza extract, can improve the content of glycyrrhizic acid, hemiglycyrrhizin isoflavone B, naringenin chalcone and other substances, can enhance the efficacy of glycyrrhiza extract, and can realize the effect of multiple targets for anti-aging, and the specific embodiments are as follows: (1) the content of beta-galactosidase in liver tissue is inhibited; (2) the level of aging-related secretory phenotype in liver tissue is reduced; (3) the Nrf2 related pathway is activated, and the level of oxidative stress is reduced; (4) the NF-kappa B related pathway is activated, and the level of chronic inflammation is reduced. Therefore, the lactobacillus crispatus CCFM1362 and the glycyrrhiza extract have great application prospect in the production of anti-aging products.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

This invention belongs to the field of biomedical technology, specifically relating to a Terminalia chebula active polypeptide, its preparation method, and its application. The preparation method uses Terminalia chebula slices as raw material, which are pulverized, homogenized with water, and then subjected to a series of enzymatic hydrolysis steps: a first hydrolysis with neutral protease, a second hydrolysis with pepsin, and a third hydrolysis with trypsin. Enzyme inactivation is performed after each hydrolysis. Subsequent steps include filtration, removal of alkaline proteins, ultrafiltration, and fine filtration to obtain the Terminalia chebula active polypeptide. The preparation method of this invention, through a three-step progressive enzymatic hydrolysis method, can efficiently prepare highly active Terminalia chebula polypeptides. The obtained Terminalia chebula active polypeptides have small molecular weight, are easily absorbed, and are non-toxic. These active polypeptides exhibit significant anti-tumor and liver fibrosis-improving effects, effectively reshaping the tumor microenvironment, enhancing anti-tumor immune responses, and repairing liver tissue damage. They have broad application prospects in the preparation of anti-tumor and liver fibrosis-improving drugs.

This disclosure describes hardware for microfluidic chips and an associated support module for facilitating operation of one or more microfluidic chips. The microfluidic chips described herein are designed for supporting multiple different tissue types, including kidney tissue, liver tissue, adipose cells, and so forth. Chip geometry facilities fluid flow through one or more channels of the chip with a particular flow rate. For example, shear forces are reduced where needed to ensure proper flow rate of fluid in the channels. The chamber geometry and the geometry of the channels ensures that a desired amount of oxygen is delivered to sample cells or tissues in a controlled manner.

This invention provides the application of Lycium barbarum polysaccharide (LBP) in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders. Research results show that LBP can significantly improve cisplatin-induced intestinal microbiota and metabolic disorders in rats, manifested by a significant reduction in CDDP-induced serum AST and ALT levels, and improvement in the degree of liver tissue lesions. Furthermore, LBP did not exhibit toxicity in rats. LBP enhanced the diversity and richness of the gut microbiota, restored the structure of dominant symbiotic bacteria, inhibited the proliferation of potentially pathogenic bacteria, and promoted the enrichment of functional bacteria related to SCFAs generation. LBP also restored abnormal metabolism in branched-chain amino acid and aromatic amino acid metabolism, one-carbon metabolism, and lipid metabolism. This invention provides a theoretical basis for the application of natural active polysaccharides in the prevention and treatment of intestinal microbiota and metabolic disorders.

The application relates to the field of biological medicine, in particular to a medicine for improving non-alcoholic fatty liver disease. The application provides the use of ML-SA1 in the preparation of a medicine for treating non-alcoholic fatty liver disease. It is found that ML-SA1 can improve non-alcoholic fatty liver disease, specifically, can reduce the accumulation of lipid droplets in hepatocytes, reduce the weight of the liver, relieve hepatocyte vacuolization and liver tissue fibrosis, and improve the related pathological indexes of non-alcoholic fatty liver disease. It is also found that the combination of ML-SA1 and other substances can more significantly improve non-alcoholic fatty liver disease.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to a TCM composition for the prevention and treatment of fatty liver, its preparation method, and its application. The TCM composition is made from raw hawthorn, dried tangerine peel, cassia seed, salvia miltiorrhiza, jujube seed, and raw licorice. Experiments show that this TCM composition can significantly reverse the increase in body weight and liver tissue weight in mice with non-alcoholic fatty liver disease, reverse the increase in serum TC, TG, LDL-C, AST, and ALT, as well as the increase in TC and TG in the liver, improve the pathological state of the liver, and protect the liver. The effect is significantly higher than that of any single component in the formula, or the absence or substitution of the formula, indicating that each herb has a synergistic effect. Furthermore, the TCM composition provided by this invention is simple to prepare, low in cost, and all herbs are medicinal and edible herbs, ensuring good safety.

The application discloses application of AML-12 exosomes in preparation of medicines for treating cholestatic liver injury, relates to the technical field of biological medicine, and discloses application of AML-12 cell-derived exosomes in preparation of medicines for preventing and treating ANIT-induced cholestatic liver injury; the treatment is manifested as reduction of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels in serum. The application proves that the AML-12 cell-derived exosomes have a significant treatment effect on ANIT-induced cholestatic liver injury, successfully opens up the application of the biological preparation in a brand-new disease field, and fills the blank of the prior art; through in-vivo experiments, it is proved that AML-12 exosome treatment can significantly reduce liver cell injury markers and alkaline phosphatase, a key index of cholestasis, in serum of ANIT model mice, and improve pathological injury of liver tissue, thereby constituting a complete curative effect evidence chain from function to morphology.

The present disclosure relates to systems, devices, and methods for subcutaneously cutting and treating tissue and cellulite with non-invasive acoustic waves. Embodiments of the present disclosure refer to systems, devices, and methods that use unfocused or planar, non-cavitating acoustic waves to induce physical effects in tissue such as dermis, fat, muscle, bone, blood vessels, liver tissue, etc. The physical effects include disruption of the fibrous extracellular matrix of the target tissue. Embodiments of the present disclosure include the application of multiple rapid acoustic pulses (e.g., shockwaves) to cause the breakdown of the fibrous extracellular matrix to reduce the appearance of cellulite or scarring in the treated area. Such unfocused or planar, non-cavitating acoustic waves can induce tissue responses such as reduced fibrosis, induction of angiogenesis or lymphangiogenesis, etc.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application relates to a method for separating and primary culturing of monopterus albus liver cells. The method comprises the following steps: obtaining monopterus albus liver tissue, perfusing the liver tissue with HBSS buffer solution without calcium and magnesium until blood is completely drained; removing the capsule, blood clots and connective tissue after rinsing, and cutting the liver tissue; sequentially using 0.02% EDTA solution, 0.25% trypsin solution and 50 U / mL collagenase IV working solution to perform three-step digestion treatment on the liver tissue fragments; obtaining a cell suspension by blowing and filtering after the digestion is completed, and then performing gradient centrifugal purification of the cells at rotating speeds of 600 rpm, 250 rpm and 80 rpm in sequence; and finally resuspending the cells in DMEM / F12 culture medium containing 10% FBS and inoculating and culturing the cells. The monopterus albus primary liver cells obtained by the method have the advantages of large quantity, high activity and high purity, and provide a reliable in-vitro model for monopterus albus related research.

The present application provides a kind of PRMT5 inhibitor, PRMT5 inhibitor includes: recombinant adeno-associated virus vector AAV-shPrmt5 and GSK3326595;Recombinant adeno-associated virus vector AAV-shPrmt5 includes the shRNA of targeting PRMT5, the nucleotide sequence of shRNA is as shown in SEQ ID No:1.The present application also provides the application of the above-mentioned PRMT5 inhibitor in the preparation of drug for improving primary biliary cholangitis, PRMT5 inhibitor is all PRMT5 gene / protein as target point, by inhibiting the expression of PRMT5 gene / protein, reduce liver tissue and spleen tissue Tfh cell and GC B cell, serum autoantibody and transaminase level, can effectively delay the disease progression of primary biliary cholangitis.

This invention discloses Lactobacillus plantarum ( Lactobacillus plants The application of Lactobacillus plantarum AY01 in the preparation of products inhibiting colorectal cancer liver metastasis is described. The Lactobacillus plantarum AY01 is deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC M 20221517. The advantages of this invention are: Lactobacillus plantarum AY01 has the characteristics of inhibiting CT26.WT cell viability, suppressing CT26.WT cell clone formation, inhibiting CT26.WT cell scratch repair, reducing its migration ability, and thus reducing tumor metastatic potential. Mouse experiments with colorectal cancer liver metastasis show that the bacterial suspension of this strain can significantly reduce the number of tumors at metastatic sites in the liver, inhibit liver tumor colonization and proliferation, reduce inflammatory cell infiltration, reduce the proportion of Ki-67 and PCNA positive cells in the liver, alleviate liver tissue damage caused by colorectal cancer liver metastasis, promote the restoration of normal liver structure, protect the liver, and exert an anti-colorectal cancer liver metastasis effect, providing theoretical support for probiotic adjuvant therapy for colorectal cancer liver metastasis.

Disclosed are implantable devices, systems, and methods of fabricating, testing, optimizing, and / or implanting such devices. An implantable device includes a body, a first intrinsic channel network formed in the body and configured to receive cells, and a second intrinsic channel network formed in the body and configured to allow for active flow of a fluid to support viability and / or function of the cells in the first intrinsic channel network. The first intrinsic channel network comprises a first channel and the second intrinsic channel network comprises a second channel, with at least segments of the first and second channels parallel to and spaced apart from each other. Cells may be suspended in a collagen matrix and introduced to the first intrinsic channel network.

The application discloses a dual-response fluorescent probe and a preparation method and detection application thereof, and belongs to the technical field of fluorescent probes. The probe is prepared by condensation reaction of 4-methyl-7-hydroxy-8-aldehyde coumarin and 4-morpholine aniline, and can simultaneously and specifically respond to peroxynitrite and viscosity. ‑ The probe specifically reacts with ONOO to generate a concentration-dependent fluorescence enhancement, has high selectivity, fast response and good linearity, and the fluorescence is significantly enhanced with the increase of viscosity. The probe has lysosome targeting properties, and can realize real-time imaging and dynamic monitoring of endogenous and exogenous ONOO ‑ in living cells, and presents a high-contrast fluorescent signal in a non-alcoholic fatty liver model mouse liver tissue slice, so that ONOO ‑ overproduction and viscosity increase in a pathological state can be accurately identified.

The application discloses an immune regulation pharmaceutical effect analysis method based on a concentrated pill of psammochloa and astragalus, which comprises the following steps: raw material extraction, animal model construction, multi-dimensional detection and data statistics. The raw materials of psammochloa and astragalus are weighed according to a specific ratio, and then are prepared into extract by ethanol decoction and concentration. After the experimental animals are grouped and administered intragastrically, the individuals are screened by the four oxygen pyrimidine modeling. The immune organs are separated, weighed, and the index is calculated. The contents of various cytokines in serum and liver tissue are detected by the ELISA method. The tissue morphology, lymphocyte proliferation and protein expression are observed by HE staining, MTT method and immunofluorescence method. The expression of key signal pathway proteins is detected by electrophoresis and other steps after the total protein is extracted, and statistical analysis is carried out. The method is systematic and comprehensive, the result is accurate and reliable, and a scientific basis is provided for the immune regulation pharmaceutical effect evaluation of the concentrated pill.

This invention relates to the field of biomedical materials technology, providing a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold material, its preparation method, and its applications. The preparation method includes: decellularizing adipose tissue to obtain adipose tissue decellularized scaffold; heparinizing the scaffold to obtain a heparinized adipose tissue decellularized scaffold; loading hepatocyte growth factor and vascular endothelial cell growth factor onto the scaffold to obtain a heparinized dual-growth factor adipose tissue decellularized scaffold; seeding induced pluripotent stem cell-derived hepatocytes onto the scaffold, and culturing to obtain a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold (RAT). This invention uses rat inguinal adipose tissue to prepare RAT material, which is low-cost, readily available, has a simple preparation process, and is easy to scale up. The RAT material of this invention can achieve liver tissue damage repair and hepatocyte regeneration, providing a new treatment strategy for acute liver failure.

This invention relates to an immunoRaman multicolor imaging kit for the prediction and assessment of liver cancer. The immunoRaman multicolor imaging reagent contains five Raman probes, which are composed of Raman spheres and antibodies attached to the surface of the Raman spheres. The Raman spheres are polymerized from triple-bonded monomers with (i) acrylic acid or (ii) styrene and acrylic acid, with a particle size of 10–100 nm and a Raman shift of 1800–2800 cm⁻¹. ‑1 The antibodies used for the five Raman probes are selected from one of the following: AFP antibody, HBX antibody, GPC3 antibody, GS antibody, and CD34 antibody. The immunoRaman multicolor imaging reagent and kit provided by this invention can achieve one-step labeling and multiplex color development of five liver cancer-related protein markers in the same liver tissue section. Compared with multiplex fluorescence immunohistochemistry, this invention has significant advantages in both efficiency and accuracy. Experiments show that the detection results of this invention are consistent with clinical diagnostic results, demonstrating great application potential.

This utility model relates to a rapid cryogenic sampler for animal liver tissue, comprising an auxiliary cylinder and a circular frame mounted on top of the auxiliary cylinder. A push hole is provided at the bottom of the circular frame, and a push plate is installed inside the push hole. A rubber stopper is connected to the bottom of the push plate, and a cylinder is connected to the bottom of the rubber stopper. A threaded post is threaded inside the cylinder. Sliding grooves are provided on the left and right sides inside the auxiliary cylinder, and sliding rods are connected to the left and right ends of the cylinder, slidingly connected to the sliding grooves. A ratchet is connected to the bottom of the threaded post extending to the bottom of the auxiliary cylinder. A rotating ring is rotatably connected to the outer end of the auxiliary cylinder, and a connecting post is connected to the bottom of the rotating ring. A pawl is rotatably connected to the bottom of the connecting post via a return shaft, and the pawl is movably connected to the ratchet. This utility model, by setting up a rotating ring, connecting post, threaded post, cylinder, and push plate in coordination, uses the rotation of the rotating ring to drive the components, causing the push plate to eject the embedding adhesive, thus smoothly retrieving the sample and embedding adhesive. This improves efficiency, ensures sample integrity, and enhances practicality.

The application discloses a plant lactobacillus gasseri strain capable of transforming ginsenoside and cassia glycoside, and application of the strain in lipid reduction and alleviation of fatty liver, and belongs to the fields of microbial technology, medicine and functional food. The core feature of the strain is that the strain can not only transform ginsenoside Rb1 into ginsenoside Rd with higher activity, but also transform cassia glycoside into cassia glycoside base, thereby improving the efficacy. The animal experiment proves that the strain and the corresponding substrate are combined to play a better role in lipid reduction and liver protection: the serum total cholesterol and triglyceride levels of high-fat diet mice can be effectively reduced, and the liver weight, liver lipid deposition and liver tissue fatty degeneration can be reduced and improved. The strain provides a new core strain and technical scheme for developing microecological preparations for preventing and / or assisting in treating hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases.

The application discloses Bacteroides multipara and application thereof for relieving metabolic dysfunction related fatty liver disease, and belongs to the technical field of microorganisms. Phocaeicola dorei The Bacteroides multipara N02 can inhibit the increase of liver and the increase of liver weight / body weight of a mouse with metabolic dysfunction related fatty liver disease without affecting the food intake, can regulate the lipid metabolism disorder of the mouse with metabolic dysfunction related fatty liver disease and relieve the liver tissue damage, and can improve the intestinal barrier function of the mouse with metabolic dysfunction related fatty liver disease. The Bacteroides multipara N02 has a very wide application prospect when used for preparing a medicine composition for relieving metabolic dysfunction related fatty liver disease and a fermented food.

The present invention relates to the Bacteroides eggerthii KGMB05336 strain and a use thereof, wherein, through the analysis of the microbiome in patients with non-alcoholic fatty liver disease that is caused by obesity, the Bacteroides eggerthii strain was identified as a significant strain. Oral administration of the Bacteroides eggerthii strain to animal models of obesity and non-alcoholic fatty liver disease caused by obesity resulted in body weight reduction, liver weight reduction, decrease of fat accumulation in visceral and liver tissues, and reduction in serum levels of AST (U / L), ALT (U / L), cholesterol (mg / dL), and glucose (mg / dL), thus demonstrating that the Bacteroides eggerthii strain can serve as a novel means for the prevention, improvement, or treatment of obesity and diseases caused by obesity, such as fatty liver, hepatomegaly, non-alcoholic fatty liver disease, and diabetes.

This invention relates to the application of PRMT4 inhibitors in the preparation of drugs for treating metabolic-associated steatohepatitis (MASH), belonging to the field of fatty liver disease treatment technology. This invention is the first to discover that PRMT4 inhibitors can serve as a novel drug target for treating MASH. Cellular experiments show that PRMT4 inhibitors inhibit palmitic acid-induced hepatocyte steatosis. Animal experiments confirm that PRMT4 inhibitors can improve hepatic fat deposition, inflammatory response, hepatocyte damage, fibrosis, and insulin resistance in high-fat fed mice, and reduce liver tissue and serum triglyceride and transaminase levels. This invention finds that PRMT4 inhibitors mainly inhibit the activation of YAP, a key transcriptional activator involved in lipid and inflammatory metabolism, and the expression of its downstream target genes. Therefore, PRMT4 inhibitors can be used to prepare drugs for treating MASH, with definite and significant efficacy, and have promising medical application prospects.

The present application discloses a rare ginsenoside composition and its application in anti-fatigue and liver protection, and relates to the technical field of biological medicine. The present application provides a rare ginsenoside composition, which is composed of Rh4, F4 and Dehydroprotopanaxatrial II, and the mass ratio of Rh4, F4 and Dehydroprotopanaxatrial II is (2-4):(2-4):1. The rare ginsenoside composition has the effect of significantly relieving physical fatigue, can reduce the decomposition and metabolism of protein to energy, eliminate fatigue, increase the liver glycogen reserve in the body, improve the fatigue resistance, has the effect of liver protection, enhances the antioxidant defense ability of liver tissue, reduces the lipid peroxidation damage, and improves the lipid metabolism disorder of liver tissue.

The application discloses application of Amomum tsao-ko extract in preparation of medicines for preventing and treating chronic alcoholic liver and intestinal injury, and belongs to the technical field of biotechnology. The extract is applied to prevention and / or treatment of alcoholic liver and intestinal injury and liver-intestinal axis disorder caused by long-term drinking, can reduce contents of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in blood plasma, improve liver and colon tissue pathological injury, repair intestinal mucosal barrier, restore liver tissue mitochondrial function and regulate expression of key factors of liver-intestinal axis; and the Amomum tsao-ko extract can effectively reduce the contents of AST and ALT in blood plasma of alcohol-induced alcoholic liver and intestinal injury model mice at a lower dose, significantly improve liver and intestinal tissue pathological injury, correct liver-intestinal axis function disorder and regulate expression of liver-intestinal axis related factors of liver tissue; the raw material of the application is from a natural product, and is convenient to collect and high in safety.

The application belongs to the technical field of medicine, and particularly relates to application of mulberry leaf ethyl acetate extract in preparation of products for treating, improving or preventing sarcopenia. The application establishes a sarcopenia model by using dexamethasone. It is proved by tests that the mulberry leaf ethyl acetate extract has the effects of reducing the content of MURF1 in serum, increasing the relative weights of gastrocnemius muscle, soleus muscle, tibialis anterior muscle and quadriceps muscle of mice, reducing the SOD activity in liver tissue, increasing the CAT activity, inhibiting the expression of GDF-8 protein in muscle, improving the pathological state of gastrocnemius muscle and reducing muscle fiber atrophy. The above results show that the mulberry leaf ethyl acetate extract plays an anti-sarcopenia effect through multi-target and multi-pathway synergistic effect, and provides a new technical scheme for drug treatment and functional food development of sarcopenia, and has a good application prospect.

The application discloses application of a combination of lyophilized powder of Haemadipsa integrifascialis and bear gall powder in preparation of a medicine for treating liver injury, and belongs to the technical field of medicines. The application proves through in-vitro HepG2 and HSC-T6 cell experiments and in-vivo CCl4-induced mouse liver injury models that the combination of the lyophilized powder of Haemadipsa integrifascialis and the bear gall powder can significantly improve the survival rate of injured liver cells, inhibit the activation and fibrosis of hepatic stellate cells, reduce the level of inflammatory factors, improve the antioxidant capacity, reduce the pathological injury of liver tissues, and the synergistic effect is significantly better than that of single medicine, and the safety is good. The application provides a new medicine combination and experimental basis for developing a new liver-protecting and anti-liver fibrosis medicine, and has important clinical application and medicine development values.